A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Rasagiline (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 29 Jun 2017 According to a Takeda Pharma media release, based on the data from CCT-001 and CCT-002 studies the company has submitted a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare in Japan for rasagiline mesylate for the treatment of Parkinson's disease.
    • 28 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 31 Mar 2016 Planned End Date changed from 1 Nov 2016 to 1 Sep 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top